Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 6Myeloid 4Sarcoma 2Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1GIST 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Magnetic Resonance Spectroscopy 15Surgical Procedures, Operative 14Radiotherapy 13Blood Specimen Collection 13Biopsy 13Gemcitabine 12fludarabine 11atezolizumab 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 7liposomal doxorubicin 5abemaciclib 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × olverembatinib × Sarcoma × Clear all
NCT03594422 2026-04-09

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Ascentage Pharma Group Inc.

Phase 1 Recruiting
100 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting
40 enrolled
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡